Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Metabolic flare phenomenon mimicking disease progression on 18Flouride– Fluorodeoxyglucose PET/CT scan in breast cancer treated with paclitaxel-based chemotherapy

Document Type : Case report

Authors
Vijay Singh
Shivangi Dixit
Manish Ora
Aftab Hasan Nazar
Department of nuclear medicine SGPGIMS, India
10.22038/aojnmb.2022.68237.1474
Abstract
18F-fluorodeoxyglucose Positron emission tomography (18F-FDG PET/CT ) is now being used as a single modality for metastatic workup and response evaluation in breast cancer. An increase in metabolic activity indicates disease progression; however, metabolic flare should be kept in mind. Metabolic flare is a well-documented phenomenon reported in metastatic breast and prostate cancer. Despite a favorable response to therapy, there is a paradoxical increase in radiopharmaceutical uptake. The flare phenomenon with various chemotherapeutic and hormonal agents is well acknowledged in bone scintigraphy. However, very few cases have been documented on PET/CT. Increased uptake may be noted after treatment is instituted. The increased osteoblastic activity is associated with the healing response of bone tumors. We report a case of treated breast cancer. She presented with metastatic recurrence after four years of initial management. The patient was started on paclitaxel chemotherapy. Serial 18F- FDG PET/CT demonstrated metabolic flare and complete metabolic response.
Keywords
Flare phenomenon
Paclitaxel
Breast cancer
Subjects
  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209–49.
  2. Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, et al. Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev APJCP. 2014; 15(8):3353–8.
  3. Drukteinis JS, Mooney BP, Flowers CI, Gatenby RA. Beyond mammography: new frontiers in breast cancer screening. Am J Med. 2013; 126(6):472–9.
  4. Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017; 8(17): 27990–6.
  5. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019; 321(3): 288–300.
  6. Schuster DM. Clinical Utility of PET scanning in Breast Cancer Management. Am J Hematol Oncol [Internet].2015 Jun 19 [cited 2020 Apr 20]; 11 (6). Available from: https://www.gotoper.com/publications/ajho/2015/2015june/clinical-utility-of-pet-scanning-in-breast-cancer-management.
  7. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2001; 19 (11):2797–803.
  8. Tu DG, Yao WJ, Chang TW, Chiu NT, Chen YH. Flare phenomenon in positron emission tomography in a case of breast cancer-a pitfall of positron emission tomography imaging interpretation. Clin Imaging. 2009; 33(6):468–70.
  9. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747–52.
  10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228–47.
  11. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med. 2009; 50(Suppl 1):122S-150S.
  12. Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O, et al. Role of 2-[18F]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in the Early Assessment of Response to Chemotherapy in Metastatic Breast Cancer Patients. Clin Breast Cancer. 2000; 1(2):156–61.
  13. Tateishi U, Gámez C, Dawood S, Yeung HWD, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. 2008 Apr [cited 2022 Jul 8]; Available from: http:// diposit.ub.edu/dspace/handle/2445/132864.
  14. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, et al. flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med Off Publ Soc Nucl Med. 1994; 35(11):1748–52.
  15. D’Amico A, Kowalska T. Paradoxal metabolic flare detected by 18F-fluorodeoxyglucose positron emission tomography in a patient with metastatic breast cancer treated with aromatase inhibitor and biphosphonate. Indian J Nucl Med IJNM off J Soc Nucl Med India. 2014; 29(1):34–7.
  16. Balasubramanian Harisankar CN, Preethi R, John J. Metabolic flare phenomenon on 18 fluoride-fluorodeoxy glucose positron emission tomography-computed tomography scans in a patient with bilateral breast cancer treated with second-line chemotherapy and bevacizumab. Indian J Nucl Med IJNM off J Soc Nucl Med India. 2015; 30(2):145–7.
  17. Reddel RR, Sutherland RL. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur J Cancer Clin Oncol. 1984; 20(11):1419–24.
  18. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer. 1993; 71(4):1266–72.
  19. Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I. Bone scan flare predicts successful systemic therapy for bone metastases. Journal of nuclear medicine. 1988 1; 29(8):1354-9.
  20. Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1995; 13(5):1123–8.
  21. Van Schelven WD, Pauwels EKJ. The flare phenomenon: far from fair and square. Eur J Nucl Med. 1994; 21(5):377–80.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 11, Issue 2
July 2023
Pages 175-180